Real-world Study of Anti-TNFa Treatment Regimes of Hyrimoz or Zessly in Patients With Crohn´s Disease

The inclusion and exclusion criteria are to ensure the enrollment of patients receiving the drug according to the label of Hyrimoz™ and the label of Zessly™. Patients observed in this study need to meet all of the following inclusion criteria and none of the exclusion criteria at enrollment: Inclusion criteria 1. Confirmed diagnosis of CD 2. Harvey-Bradshaw Index (HBI) ≥ 5 3. Treatment failure upon steroids / topical budesonide with or without immunosuppressants 4. Males and females ≥ 18 years of age at enrollment 5. Biologic-naive patients scheduled to receive Hyrimoz™ or Zessly™ and patients already receiving Hyrimoz™ or Zessly™ according to the label and at the discretion of the investigator for up to three months prior enrollment 6. Provision of signed informed consent form Exclusion criteria 1. Patients with CD in clinical remission (HBI \< 5) 2. Hemoglobin \< 8.5 g/dL 3. Patients at imminent risk of scheduled intestinal surgery (stenosis, strictures, internal fistula) 4. Any contraindications to Hyrimoz™ or Zessly™ according to the prescribing recommendations in each country 5. Participation in an interventional clinical trial for immune-mediated inflammatory diseases (IMIDs) or having received any investigational agent or procedure within 30 days prior to enrollment (consenting)